Related Experiment Video
Updated: May 6, 2026
Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
[Advanced research of fibroblast growth factor receptor in non-small cell lung cancer]
Abstract:
Lung cancer is severely threatening human health. In recent years, the treatment for lung adenocarcinoma has made a great progress, targeted therapy has been widely applied in clinic, and benefits amount of patients. However, in squamous cell lung cancer, the incidence of epidermal growth factor receptor (EGFR) gene mutant and ALK fusion gene are low,and targeted therapy like Tarceva and crizotinib, can hardly work. Since the fibroblast growth factors (fibroblast growth factor, FGF) pathway is considered to be related to tumor cell proliferation, metastasis and angiogenesis, more and more researches proved the amplification of fibroblast growth factor receptor (FGFR) in squamous cell lung cancer. Experiments in vivo and in vitro found that blocking FGF pathway could reduce the proliferation of tumor cells and inhibit metastasis. The FGF pathway might be a new target for treatment of squamous cell lung cancer. This article reviews the effect of FGFR in tumorigenesis,as well as the prospect as a therapeutic target in non-small cell lung cancer.
Insights
Fibroblast Growth Factor Receptor (FGFR) pathway is implicated in squamous cell lung cancer. Blocking this pathway shows promise for inhibiting tumor growth and metastasis, offering a new therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Context:
- Lung cancer remains a significant global health threat.
- Targeted therapies have advanced lung adenocarcinoma treatment but are less effective for squamous cell lung cancer due to low rates of EGFR mutations and ALK fusions.
- The fibroblast growth factors (FGF) pathway is increasingly recognized for its role in tumor progression.
Purpose:
- To review the role of fibroblast growth factor receptor (FGFR) in the development of squamous cell lung cancer.
- To explore the therapeutic potential of targeting the FGF pathway in non-small cell lung cancer.
Summary:
- Amplification of FGFR is observed in squamous cell lung cancer.
- In vitro and in vivo studies demonstrate that inhibiting the FGF pathway reduces tumor cell proliferation and metastasis.
- The FGF pathway presents a potential novel therapeutic target for squamous cell lung cancer.
Impact:
- This review highlights FGFR as a promising therapeutic target for squamous cell lung cancer, addressing limitations of current treatments.
- Findings may guide future research and clinical development of targeted therapies for this challenging cancer type.
